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High Seroprevalence of Anti-Mycoplasma Fermentans Antibodies
in Patients with Malignant Aphthosis
To the Editor:
Mycoplasmas are wall-less bacteria causing infections of mucosal
tissue. Many mycoplasmas are commensals, others, such as Myco-
plasma (M) fermentans, are associated with rheumatoid arthritis
and other joint disorders (Schaeverbeke et al, 1996). Most, if not
all, mycoplasmas contain macrophage activating components.
Studies on a macrophage activator from mycoplasmas, compar-
able in activity with the lipopolysaccharide of gram-negative
bacteria, led to the identi¢cation of macrophage-activating lipo-
peptide (MALP)-2 from M. fermentans. MALP-2 is a small lipo-
peptide originating from MALP-404, a 40 kDa large lipoprotein
(Calcutt et al, 1999). MALP-2 and other mycoplasmal lipoproteins
have an unusual N-terminus. It consists of a cystein bearing a di-
hydroxypropyl group in thioether linkage. Both hydroxy groups
are esteri¢ed with long chain fatty acids, whereas the amino
group is free. This distinguishes mycoplasmal lipoproteins from
those in walled bacteria. Mycoplasmal lipoproteins are exception-
ally good antigens, because they have a built-in adjuvant site in
the form of the lipid-substituted N-terminus. Thus, MALP-404
is an immunodominant determinant in M. fermentans. MALP-
404 is expressed by most M. fermentans strains, including those
isolated from the joints of patients with reactive arthritis (Mˇhl-
radt, unpublished).
Like other bacterial proteins, MALP-404 contains the peptide
motif -G- - - - - -F, which can be presented by HLA-B51 (Falk et al,
1995). This transplantation antigen is associated with malignant
aphthosis (Sakane et al, 1999). Malignant aphthosis (Adamantiades^
Behc et’s disease) is a chronic, multisystemic in£ammatory disor-
der, which is clinically characterized by relapsing oral aphthous
and genital ulcers, ocular, and vascular lesions. The disease may
a¡ect small and large vessels in almost all organs. Malignant
aphthosis is a universal rare disorder with varying prevalence, oc-
curring endemically in the Eastern Mediterranean area and in Cen-
tral and East Asia, with a peak onset in the third decade of life
(Zouboulis, 1999). A microbial infection has been implicated in the
development of the disease to explain the strong in£ammatory re-
actions observed (Zouboulis and May, in press), the activation of
monocytes and macrophages, and the induction of proin£amma-
tory cytokines and chemokines detected (Zouboulis et al, 2000;
Alpsoy et al, 2003). Recently, several reports demonstrated that
crude fractions of lipoproteins derived from di¡erent mycoplasma
strains showed macrophage-stimulatory activities by inducing the
production of proin£ammatory cytokines. For all these reasons,
we investigated the presence of antibodies against MALP-404 in
the sera of patients with malignant aphthosis and examined a pos-
sible correlation of M. fermentans infection with the disease in an
ethic committee-approved case^control study.
The 22 patients [(10 female, 12 male; median age 37 y; originat-
ing from Germany (n¼ 3), Turkey (n¼12), and other countries
(n¼ 7)] and 14 gender-, age-, and land of origin-matched healthy
controls [(seven female, seven male; median age 36 y; originating
from Germany (n¼ 4), Turkey (n¼ 7), and other countries
(n¼ 3)] were recruited after providing written consent. Patients
ful¢lled the criteria of the International Study Group for Behc et’s
Disease (1990). The presence of the MALP-404 antigen was de-
tected in the serum of the subjects examined by the western blot
method. Demographic and background characteristics were dis-
played using summary statistics.The primary and secondary vari-
ables were evaluated using w2 tests. For all comparisons, a
signi¢cance level of 0.05 was applied.
From the 22 patients with malignant aphthosis, seven (32%)
were MALP-404-positive; among them three patients (14%) with
Figure1. Western blot of selected sera from patients with malignant
aphthosis (Adamantiades^Behc et’s disease). Mycoplasma lipoprotein
antigens were enriched by cold octyl glucoside extraction of aM. fermentans
strain isolated from the knee joint of a rheumatoid arthritis patient. The
antigen mixture was separated on sodium dodecyl sulfate^polyacrylamide
gel electrophoresis and electroblotted to a PVDF membrane. Lanes 1 to 4:
sera from patients with malignant aphthosis; lane 5: monoclonal antibodies
against the indicated lipoproteins (positive control); lane 6: molecular
weight markers. Note typical positive reaction to MALP-404 in lane 2,
and strong reaction with an unidenti¢ed M. fermentans antigen in lane 1.
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strong antibody signals indicating a previous or further active infec-
tion with M. fermentans. In contrast, MALP-404 antibodies were
not detected in any of the 14 matched controls examined (odds
ratios 46.07 and 2.05, respectively; po0.05). Four of the seven
MALP-404-positive patients (57%) but also nine of the 15
MALP-404-negative patients (60%) were HLA-B51-positive (odds
ratio 0.89, not signi¢cant). The presence of the MALP-404 antigen
did not correlate with any demographic data, the clinical signs or
the prognostic factors of the disease (not signi¢cant).
These data suggest that a high percentage of patients with ma-
lignant aphthosis present with antibodies against M. fermentans.
MALP-404 has been shown to be subject to site-speci¢c proteo-
lysis between residues 14 and 15 of the mature lipoprotein, result-
ing in the cell-bound MALP-2 and soluble released fragment
products (Davis and Wise, 2002). On the other hand, MALP-
404 is responsible for macrophage activation and macrophages
of healthy donors have been strongly activated by serum of pa-
tients with malignant aphthosis (Alpsoy et al, 2003). Therefore,
the possibility exists that a M. fermentans infection in patients with
malignant aphthosis predisposes these patients to a cross-reactive
autoimmune response and precipitates the disease (Sakane et al, 1999).
Christos C. Zouboulis, Julia R. Turnbull, and Peter F. Mˇhlradtn
Department of Dermatology, University Medical Center Benjamin
Franklin,The Free University of Berlin, Berlin, Germany
nImmunobiology Research Group, Gesellschaft fˇr
Biotechnologische Forschung mbH, Braunschweig, Germany
REFERENCES
Alpsoy E, KodeljaV, Goerdt S, Orfanos CE, Zouboulis ChC: Serum of patients with
Behc et’s disease induces classical (pro-in£ammatory) activation of human
macrophages in vitro. Dermatology 206:225^232, 2003
Calcutt MJ, Kim MF, Karpas AB, Mˇhlradt PF,Wise KS: Di¡erential post-transla-
tional processing confers intraspecies variation of a major surface lipoprotein
and macrophage-activating lipopeptide (MALP-2) of Mycoplasma fermentans.
Infect Immun 67:760^771, 1999
Davis KL, Wise KS: Site-speci¢c proteolysis of the MALP-404 lipoprotein deter-
mines the release of a soluble selective lipoprotein-associated motif-containing
fragment and alteration of the surface phenotype of Mycoplasma fermentans. In-
fect Immun 70:1129^1135, 2002
Falk K, R˛tzschke O,Takiguchi M, GnauV, Stefanovic S, Jung G, Rammensee H-G:
Peptide motifs of HLA-B51, -B52 and -B78 molecules, and implications for
Behc et’s disease. Int Immunol 7:223^228, 1995
International Study Group for Behc et’s Disease: Criteria for diagnosis of Behc et’s dis-
ease. Lancet 335:1078^1080, 1990
Sakane T, Takeno M, Suzuki N, Inaba G: Behc et’s disease. N Engl J Med 341:
1284^1291, 1999
Schaeverbeke T, Gilroy CB, BeŁ beŁ ar C, Dehais J, Taylor-Robinson D: Mycoplasma fer-
mentans in joints of patients with rheumatic arthritis and other joint disorders.
Lancet 347:1418, 1996
Zouboulis ChC: Epidemiology of Adamantiades-Behc et’s disease. Ann Med Intern
150:488^498, 1999
Zouboulis ChC, MayT: Pathogenesis of Adamantiades-Behc et’s disease. J Med Micro-
biol Immunol, in press
Zouboulis ChC, Katsantonis J, Ketteler R, et al : Adamantiades-Behc et’s disease: In-
terleukin-8 is increased in serum of patients with active oral and neurological
manifestations and is secreted by small vessel endothelial cells. Arch Dermatol
Res 292:279^284, 2000
Lack of Evidence for the Presence of SimianVirus 40 DNA in
Cutaneous Lymphomas
To the Editor:
Cutaneous lymphomas are the second most common extranodal
non-Hodgkin lymphoma (Connors et al, 2002) with an incidence
of 1 in 100,000 (Burg et al, 1994). The etiology remains unclear;
infectious agents (Goodlad et al, 2000; Erkek et al, 2001), as one
of the possible causes of the disease are discussed by several
authors. Simian virus 40 (SV40) is a DNA virus that can induce
various tumors in hamsters and rodents (Cicala et al, 1993), and
whose oncogenic potential has been demonstrated in multiple
human tumors, such as brain and bone tumors or mesotheliomas
(Jasani et al, 2001).
The capacity of SV40 to promote proliferation is due to its
large T antigen, which is primarily responsible for virus replica-
tion, and cell transformation. SV40 was mainly transmitted to
humans between 1955 and 1963 in contaminated batches of polio
vaccine (Kops, 2000). Although large epidemiologic studies with
patients vaccinated with the tainted vaccine did not show an in-
creased incidence of cancer (Carroll-Pankhurst et al, 2001), SV40
links to cancer grow stronger (Ferber, 2002).
Two recent studies report on the presence of SV40 in human
lymphomas (Shivapurkar et al, 2002; Vilchez et al, 2002). Large T
antigen DNA sequences were detected by polymerase chain reac-
tion (PCR) in 43% of all non-Hodgkin lymphomas and 9% of all
Hodgkin lymphomas; however, the association of the polyoma
virus with cutaneous lymphomas has not been investigated yet.
In this study, we screened the presence of the large T antigen
region of SV40 in 43 cutaneous lymphoproliferative disorders.
Fifteen cases of mycosis fungoides, 12 primary cutaneous B cell
lymphomas (eight extranodal marginal zone B cell lymphomas
of mucosa associated lymphoid tissue-type, three follicular lym-
phomas, one di¡use large B cell lymphoma), six cases of lympho-
matoid papulosis, and ten atypical lymphocytic in¢ltrates
(pseudolymphomas) with a predominant T cell immunopheno-
type were included in this study. Specimens were gathered from
diagnostic skin biopsies of Caucasian patients from the Depart-
ment of Dermatology, Ludwig-Maximilians-University (Mu-
nich, Germany). The mean age of our 43 patients was 61 y (SD
20 years, range 25^97 y). The patients included in the study lived
in Germany, none of our patients had undergone an organ trans-
plantation or showed features of immunosuppression. The his-
tologic diagnosis was made due to the morphology and immu-
nophenotype of the in¢ltrates.
In order to detect intralesional presence of SV40 large T anti-
gen 35 formalin-¢xed and para⁄n-embedded skin biopsies and
eight frozen tissue biopsies were cut in one 10 mm section each
and stained with hematoxylin.
The entire lymphocytic in¢ltrate (approximately 2000^4000
cells) was dissected with a PixCell II Laser Capture Microdissection
System (Arcturus Engineering Inc., MountainView, California).
The captured cells were immediately transferred to proteinase
K enriched digestion bu¡er. After an overnight incubation at
501C, proteinase was heat-inactivated. Presence of a su⁄cient
amount of DNA was assured by amplifying a fragment of the
b-globin gene (primers PCO3/KM38 (Saiki et al, 1985)) as an in-
ternal control.
For detection of SV40 large T antigen sequences, two di¡erent
sets of primers (PYV-forward/PYV-reverse and SV-forward/SV-
reverse) were used (Gamberi et al, 2000; David et al, 2001), ampli-
fying a 172 bp, respectively, a 574 bp product. PCRwere carried
out in a 30 mL reaction volume, containing 1PCR bu¡er (Ap-
plied Biosystems, Branchburg, New Jersey), 200 mM each deoxy-
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